Optimized sequence of drug administration and schedule leads to improved dose delivery for gemcitabine and paclitaxel in combination: A phase I trial in patients with recurrent ovarian cancer

International Journal of Gynecological Cancer

Volumn 16, Issue 2, 2006, Pages 507-514

  Poole, C J ^a,d   Perren, T ^b   Gawande, S ^c   Ridderheim, M ^c   Cook, J ^d   Jenkins, A ^b   Roychowdhury, D ^c  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^c ELI LILLY AND COMPANY   (United States)

^d CITY HOSPITAL   (United Kingdom)

Author keywords

Drug sequence; Gemcitabine; MTD; Paclitaxel; Phase I; Recurrent ovarian cancer; Schedule

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; CA 125 ANTIGEN; CARBOPLATIN; CHLORPHENIRAMINE; CIMETIDINE; CISPLATIN; DEXAMETHASONE; GEMCITABINE; PACLITAXEL; RANITIDINE;

ADULT; AGED; ANAMNESIS; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DRUG DOSE REGIMEN; FEMALE; HUMAN; HYPERGLYCEMIA; HYPOCALCEMIA; LEUKOPENIA; LUNG INFILTRATE; MAXIMUM TOLERATED DOSE; NEUROTOXICITY; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT CANCER; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PACLITAXEL;

EID: 33646057721     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2006.00466.x     Document Type: Article

References (38)

1. Greenlee RT Hill-Harmon MB Murray T Thun M Cancer statistics 2001 CA Cancer J Clin 2001 51 15 36
2. McGuire WP Ozols RF Chemotherapy of advanced ovarian cancer Semin Oncol 1998 25 340 8
3. Ozols RF Schwartz PE Eifel PJ Ovarian cancer, fallopian tube carcinoma, and peritoneal carcinoma In DeVita VT Hellman S Rosenberg SA eds Cancer: principles and practice of oncology 5th edn Philadelphia, PA Lippincott-Raven Press 1997 1502 39
4. Markman M Hoskins W Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population J Clin Oncol 1992 10 513 4
5. Lund B Hansen O Theilade K et al Phase II study of gemcitabine (2′,2′-difluorodeoxycytidine) in previously treated ovarian cancer patients J Natl Cancer Inst 1994 86 1530 3
6. Friedlander M Millward MJ Bell D et al A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer Ann Oncol 1998 9 1343 5
7. Kudelka A Verschraegen C Edwards C et al A preliminary report of a phase 2 study of gemcitabine in women with platinum refractory mullerian (ovarian, fallopian tube and primary peritoneal) carcinomas [abstract] Proc Am Soc Clin Oncol 1999 18 377a. Abstract 1457
8. von Minckwitz G Bauknecht T Visseren-Grul CM et al Phase II study of gemcitabine in ovarian cancer Ann Oncol 1999 10 853 5
9. Ozols RF The role of gemcitabine in the treatment of ovarian cancer Semin Oncol 2000 1 Suppl. 2 40 7
10. McGuire WP Rowinsky EK Rosenshein NB et al Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms Ann Intern Med 1989 111 273 9
11. Thigpen JT Blessing JA Ball H et al Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study J Clin Oncol 1994 12 1748 53
12. Einzig AI Wiernik PH Sasloff J et al Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma J Clin Oncol 1992 10 1748 53
13. Gore ME Levy V Rustin G et al Paclitaxel (taxol) in relapsed and refractory ovarian cancer: the UK and Eire experience Br J Cancer 1995 72 1016 9
14. Gore ME Preston N A'Hern RP et al Platinum-taxol non-cross resistance in epithelial ovarian cancer Br J Cancer 1995 71 1308 10
15. Kroep JR Giaccone G Voorn DA et al Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer J Clin Oncol 1999 17 2190 7
16. Poole CJ Cook J Hogberg T et al A phase I clinical trial of gemcitabine and paclitaxel in patients with recurrent epithelial ovarian cancer [abstract] Ann Oncol 1996 7 Suppl. 5 72 Abstract 341
17. Rothenberg ML Sharma A Weiss GR et al Phase I trial of paclitaxel and gemcitabine administered every two weeks in patients with refractory solid tumors Ann Oncol 1998 9 733 8
18. Fontaine C Neyns B Grauwels D et al Phase I/II study of paclitaxel and gemcitabine in patients with advanced non-small cell lung cancer (NSCLC) [abstract] Proc Am Soc Clin Oncol 1999 18 503a Abstract 1940
19. Giaccone G Smit EF van Meerbeeck JP et al A phase I-II study of gemcitabine and paclitaxel in advanced non-small-cell lung cancer patients Ann Oncol 2000 11 109 12
20. Rinaldi DA Lormand NA Brierre JE et al Phase I trial of gemcitabine administered as a standard and constant dose-rate infusion, in combination with paclitaxel in patients with advanced solid tumors (LOA-2) Am J Clin Oncol 2002 25 523 7
21. Fleming DR Glisson SD Bhupalam L et al Phase I study of paclitaxel and day 1/day 8 gemcitabine in patients with solid malignancies Am J Clin Oncol 2000 23 349 52
22. Garcia-Arroyo FR Constenla M Lorenzo I et al Phase I study of gemcitabine (GEM) & paclitaxel (TX) in patients (P) with advanced urothelial cancer (AUC) [abstract] Ann Oncol 2000 11 Suppl. 4 79 Abstract 351P
23. Iaffaioli RV Tortoriello A Santangelo M et al Phase I dose escalation study of gemcitabine and paclitaxel plus colony-stimulating factors in previously treated patients with advanced breast and ovarian cancer Clin Oncol 2000 12 251 5
24. Poole CJ Perren T Hogberg T et al Phase 1 study to investigate alternate sequencing of the combination of gemcitabine and paclitaxel in ovarian carcinoma [abstract] Eur J Cancer 1997 33 Suppl. 8 S121 Abstract 543
25. Einhorn LH Raghavan D Kindler H et al A phase I trial of gemcitabine plus paclitaxel combination therapy in patients with refractory solid tumors [abstract] Proc Am Soc Clin Oncol 1998 17 207a Abstract 796
26. De Pas T de Braud F Danesi R et al Phase I and pharmacologic study of weekly gemcitabine and paclitaxel in chemo-naive patients with advanced non-small-cell lung cancer Ann Oncol 2000 11 821 7
27. Ryan DP Lynch TJ Grossbard ML et al A phase I study of gemcitabine and docetaxel in patients with metastatic solid tumors Cancer 2000 88 180 5
28. Meluch AA Greco FA Burris HA III. et al Paclitaxel and gemcitabine chemotherapy for advanced transitional cell carcinoma the urothelial tract: a phase II trial of the Minnie Pearl cancer research network J Clin Oncol 2001 19 3018 24
29. Murad AM Guimaraes RC Aragao BC et al Gemcitabine and paclitaxel as salvage therapy in metastatic breast cancer Oncology 2001 15 Suppl. 3 25 7
30. Colomer R Llombart A Lluch A et al Paclitaxel/gemcitabine administered every two weeks in advanced breast cancer: preliminary results of a phase II trial Semin Oncol 2000 27 Suppl. 2 20 4
31. Androulakis N Kouroussis C Kakolyris S et al Salvage treatment with paclitaxel and gemcitabine for patients with non-small-cell lung cancer after cisplatin- or docetaxel-based chemotherapy: a multicenter phase II study Ann Oncol 1998 9 1127 30
32. Garcia AA O'Meara A Bahador A et al Phase II study of gemcitabine and weekly paclitaxel in recurrent platinum-resistant ovarian cancer Gynecol Oncol 2004 93 493 8
33. Geertsen P Hansen M Stroyer I et al Combination chemotherapy with platinum, paclitaxel, and gemcitabine in patients with relapsed ovarian carcinoma [abstract] Proc Am Soc Clin Oncol 1999 18 361a. Abstract 1395
34. Harries M Moss C Perren T et al A phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer Br J Cancer 2004 91 627 32
35. Look KY Bookman MA Schol J et al Phase I feasibility trial of carboplatin, paclitaxel and gemcitabine with previously untreated epithelial ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study Gynecol Oncol 2004 92 93 100
36. Ozols RF Bundy BN Greer BE et al Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resection stage III ovarian cancer: a Gynecologic Oncology Group study J Clin Oncol 2003 21 3194 200
37. Copeland LJ Bookman M Trimble E Clinical trials of newer regimens for treating ovarian cancer: the rationale for Gynecologic Oncology Group Protocol GOG 182-ICON 5 Gynecol Oncol 2003 90 S1 7
38. Du Bois A Pfisterer J Meier W et al Improving first-line therapy of advanced ovarian cancer - the AGO Ovarian Cancer Study Group perspective Int J Gynecol Cancer 2003 13 Suppl. 2 169 71